Response to Letter Regarding Article, “Association of Circulating Cholesteryl Ester Transfer Protein Activity With Incidence of Cardiovascular Disease in the Community”
We thank Dr Quintão for correctly noting that the recent prospective analysis from our group using Framingham Offspring Study data indicated an inverse association of plasma cholesteryl ester transfer protein activity with the incidence of cardiovascular disease events,1 whereas a prior publication noted a direct relation of plasma cholesteryl ester transfer protein activity with the prevalence of coronary heart disease.2 We submit that differences in study design (prospective versus cross-sectional) likely account for these differences. We also submit that the risk of cardiovascular disease associated with any potential biomarker is best evaluated by longitudinal studies. Indeed, a recent study reported a similar inverse relation of plasma cholesteryl ester transfer protein concentration and cardiovascular mortality in a high-risk sample.3
Vasan RS, Pencina MJ, Robins SJ, Zachariah JP, Kaur G, D'Agostino RB, Ordovas JM. Association of circulating cholesteryl ester transfer protein activity with incidence of cardiovascular disease in the community. Circulation. 2009; 120: 2414–2420.
Ordovas JM, Cupples LA, Corella D, Otvos JD, Osgood D, Martinez A, Lahoz C, Coltell O, Wilson PW, Schaefer EJ. Association of cholesteryl ester transfer protein-TaqIB polymorphism with variations in lipoprotein subclasses and coronary heart disease risk: the Framingham study. Arterioscler Thromb Vasc Biol. 2000; 20: 1323–1329.
Ritsch A, Scharnagl H, Eller P, Tancevski I, Duwensee K, Demetz E, Sandhofer A, Boehm BO, Winkelmann BR, Patsch JR, März W. Cholesteryl ester transfer protein and mortality in patients undergoing coronary angiography: the Ludwigshafen Risk and Cardiovascular Health study. Circulation. 2010; 121: 366–374.